Tough times for Tecen­triq as NICE once again slaps down Roche's im­munother­a­py — slight ben­e­fit not worth price

The UK drug-pric­ing watch­dog has again nixed Roche and its can­cer im­munother­a­py Tecen­triq.

The Na­tion­al In­sti­tute for Health and Care Ex­cel­lence’s lat­est fil­ing is for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.